Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Frontiers in ImmunologyOpen Access

Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: a case report and literature review

View Full Paper
Ask AI
Bookmark
Share

Authors

XJXiaoyu JingDLDongjun LiSSShao Bo Su

Discussion

Loading...

Member takes

Overview

Case report reveals daratumumab effectively improves outcomes in pediatric patients post-HSCT, suggesting a new treatment pathway.

Key Points

  • Daratumumab induced a rapid and sustained response in treating severe refractory hemolytic anemia and immune-mediated thrombocytopenia.
  • The treatment improved platelet counts after prior therapies failed, highlighting its potential in resistant cases.
  • The patient, presenting with aplastic anemia post-HSCT, achieved normal platelet levels after re-initiating daratumumab therapy.
  • Delayed recovery of humoral immunity was the only significant adverse effect, indicating careful monitoring is needed.

Cite This Study

Jing et al. (2025) studied this question.

synapsesocial.com/papers/68c1a91354b1d3bfb60e2785https://doi.org/10.3389/fimmu.2025.1625365
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Successful eradication of de novo HLA antibodies with daratumumab in immune-mediated cytopenias after allogeneic stem cell transplantation: a case report2026
  2. 2Posttransplant Autoimmune Hemolytic Anemia with Anti-D Specificity Successfully Treated with Daratumumab: A Case Report2024 · 3 citations
  3. 3A case for CD38 targeted therapy in multi-refractory immune thrombocytopenia2025
  4. 4Efficacy of daratumumab in treatment of relapsed and/or refractory warm autoimmune hemolytic anemia in children2025
  5. 5Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias2026